Tepotinib with an EGFR-Tyrosine Kinase Inhibitor (TKI) in Patients with EGFR-mutant MET-amplified NSCLC: A Case Series

被引：0
|
作者：
Le, X. [1 ]
Eisert, A. [2 ]
Himpe, U. [3 ]
De Bondt, C. [4 ]
Mazieres, J. [5 ]
Petrini, I. [6 ]
Tho, L. M. [7 ]
Ahmad, A. [8 ]
Lam, W. -S. [9 ]
Chik, Y. K. J. [10 ]
Lee, W. C. K. [11 ]
Yang, T. -Y. [12 ]
Joshi, K. [13 ,14 ]
Berghoff, K. [13 ]
Vlassak, S. [13 ]
Karachaliou, N. [13 ]
v. d. Wekken, A. [15 ]
机构：
[1] Univ Texas MD Anderson Canc Ctr, Houston, TX USA
[2] Univ Hosp Cologne, Ctr Integrated Oncol Aachen Bonn Cologne Duesseld, Cologne, Germany
[3] AZ Delta Roeselare Menen Torhout, Roeselare, Belgium
[4] Antwerp Univ Hosp, Edegem, Belgium
[5] Univ Paul Sabatier, CHU Toulouse, Toulouse, France
[6] Univ Hosp Pisa, Pisa, Italy
[7] Pantai Hosp Kuala Lumpur, Kuala Lumpur, Malaysia
[8] Beacon Hosp, Petaling Jaya, Selangor, Malaysia
[9] Western Haematol & Oncol Clin, Perth, Australia
[10] Queen Elizabeth Hosp, Hong Kong, Peoples R China
[11] Prince Wales Hosp, Hong Kong, Peoples R China
[12] Taichung Vet Gen Hosp, Taichung, Taiwan
[13] Merck Healthcare KGaA, Darmstadt, Germany
[14] ICON Plc, Dublin, Ireland
[15] Univ Groningen, Univ Med Ctr Groningen, Groningen, Netherlands
来源：
JOURNAL OF THORACIC ONCOLOGY | 2022年 / 17卷 / 09期
关键词：
Tepotinib; EGFR; MET;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
EP08.02-16
引用
收藏
页码：S483 / S484
页数：2
相关论文
共 50 条
  • [21] Resistance mechanisms to dual EGFR and MET inhibition in patients with EGFR-mutant MET-amplified non-small cell lung cancer
    Wang, K.
    Du, R.
    Roy, S.
    Vokes, N.
    Elamin, Y. Y.
    Hume, C. Bueno
    Skoulidis, F.
    Gay, C.
    Blumenschein, G.
    Fossella, F.
    Tsao, A.
    Lee, J. J.
    Rinsurongkawong, W.
    Rinsurongkawong, V.
    Gibbons, D.
    Vaporciyan, A.
    Zhang, J.
    Heymach, J.
    Altan, M.
    Le, X.
    [J]. ANNALS OF ONCOLOGY, 2022, 33 (07) : S1016 - S1016
  • [22] MET Status before Tyrosine Kinase Inhibitor (TKI)-Start Predicts Treatment Responses in EGFR-Mutant Lung Adenocarcinoma
    Meyer, A-S K.
    Marienfeld, R.
    Rudiger, S.
    Muller, P.
    Moller, P.
    Schumann, C.
    Lennerz, J. K.
    [J]. LABORATORY INVESTIGATION, 2014, 94 : 488A - 488A
  • [23] TPX-0005 with an EGFR Tyrosine Kinase Inhibitor (TKI) Overcomes Innate Resistance in EGFR Mutant NSCLC
    Rosell, R.
    Karachaliou, N.
    Cui, J. J.
    Chaib, I.
    Berenguer, J.
    Bratch, J.
    Li, X.
    Yang, J.
    Drozdowskyj, A.
    Codony Servat, C.
    Codony Servat, J.
    Gimenez-Capitan, A.
    Viteri, S.
    Molina-Vila, M.
    Lopez-Vivanco, G.
    Vergnenegre, A.
    Sanchez-Torres, J. M.
    Provencio, M.
    De Marinis, F.
    Passaro, A.
    Carcereny, E.
    Reguart, N.
    Garcia Campelo, R.
    Ignatius Ou, S.
    Cardona, A.
    Cao, P.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S2230 - S2230
  • [24] MET Status before Tyrosine Kinase Inhibitor (TKI)-Start Predicts Treatment Responses in EGFR-Mutant Lung Adenocarcinoma
    Meyer, A-S K.
    Marienfeld, R.
    Rudiger, S.
    Muller, P.
    Moller, P.
    Schumann, C.
    Lennerz, J. K.
    [J]. MODERN PATHOLOGY, 2014, 27 : 488A - 488A
  • [25] Tepotinib plus gefitinib in patients with EGFR-mutant NSCLC with MET amplification (METamp): final analysis of INSIGHT
    Liam, Chong Kim
    Ahmad, Azura Rozila
    Hsia, Te-Chun
    Zhou, Jianying
    Kim, Dong-Wan
    Cheng, Ying
    Lu, Shun
    Shin, Sang Won
    Yang, James Chih-Hsin
    Zhang, Yiping
    Zhao, Jun
    Bruns, Rolf
    Johne, Andreas
    Wu, Yi-Long
    [J]. ONCOLOGY RESEARCH AND TREATMENT, 2022, 45 (SUPPL 3) : 177 - 177
  • [26] Tepotinib plus Gefitinib in Patients with EGFR-Mutant NSCLC with MET Amplification (METamp): Final Analysis of INSIGHT
    OHara, R.
    Liam, C. Kin
    Ahmad, A. Rozila
    Hsia, T. -C.
    Zhou, J.
    Kim, D. -W.
    Soo, R. Andrew
    Cheng, Y.
    Lu, S.
    Shin, S. Won
    Yang, J. Chih-Hsin
    Zhang, Y.
    Zhao, J.
    Bruns, R.
    Johne, A.
    Wu, Y. -L.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (03) : E6 - E7
  • [27] Improved survival in patients with unresectable stage III EGFR-mutant adenocarcinoma with upfront EGFR-tyrosine kinase inhibitors
    Wang, Sheng-Yuan
    Lai, Ching-Han
    Chen, Chian-Wei
    Yang, Szu-Chun
    Chang, Chao-Chun
    Lin, Chia-Ying
    Yen, Yi-Ting
    Tseng, Yau-Lin
    Su, Po-Lan
    Lin, Chien-Chung
    Su, Wu-Chou
    [J]. THORACIC CANCER, 2022, 13 (02) : 182 - 189
  • [28] Predicting duration of response to EGFR TKI among EGFR-mutant NSCLC patients.
    Sakr, Lama
    Kasymjanova, Goulnar
    Small, David I.
    Cohen, Victor
    Galvis, Luisa
    Pepe, Carmela
    Agulnik, Jason Scott
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [29] Osimertinib and other third-generation EGFR TKI in EGFR-mutant NSCLC patients
    Remon, J.
    Steuer, C. E.
    Ramalingam, S. S.
    Felip, E.
    [J]. ANNALS OF ONCOLOGY, 2018, 29 : I20 - I27
  • [30] Clinical and molecular feature-based nomogram model for predicting benefit from bevacizumab combined with first-generation EGFR-tyrosine kinase inhibitor (TKI) in EGFR-mutant advanced NSCLC
    Yongchang Zhang
    Liang Zeng
    Xiangyu Zhang
    Yizhi Li
    Lingli Liu
    Qinqin Xu
    Haiyan Yang
    Wenjuan Jiang
    Analyn Lizaso
    Luting Qiu
    Ting Hou
    Jun Liu
    Ling Peng
    Nong Yang
    [J]. BMC Medicine, 19
12345